+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Long-term risk of second malignancies in women after breast conservation therapy for ductal carcinoma in situ or early-stage breast cancer



Long-term risk of second malignancies in women after breast conservation therapy for ductal carcinoma in situ or early-stage breast cancer



Breast Cancer Research and Treatment 170(1): 45-53



Women with ductal carcinoma in situ (DCIS) or early-stage breast cancer have an excellent prognosis, but their risk of developing second malignant neoplasms (SMNs) is not well established. We analyzed SMNs in a large cohort with long follow-up after breast conservation therapy. The study population comprised 755 women with DCIS (n = 135) or stage I-II breast carcinoma (n = 620). Subjects were aged 25-89 (median 55) years when they underwent breast-conserving surgery followed by radiotherapy to the entire breast (60-68Gray) between 1992 and 2001. Additional treatment included hormonal therapy and/or chemotherapy based on clinical characteristics. SMNs were grouped by site. The rate of SMNs over time was determined using the Kaplan-Meier method. To compare the probability of developing SMNs overall and for specific organs or sites, probability estimates were obtained for a 55-year-old female from the Surveillance, Epidemiology, and End Results Program (SEER). Median follow-up from radiotherapy was 13.8 years. The 15-year age-adjusted probability of developing any SMN was 12.0%, close to the SEER rate of 12.1% for a non-breast malignancy. Systemic therapy and higher-dose radiotherapy (> 63 Gray) were not associated with significantly increased risks of SMNs. Compared to SEER, significantly increased risk was noted for gynecologic cancers and melanoma. Most SMNs were unrelated to treatment, and the 15-year incidence was similar to that of cancer in the SEER control group-findings that should be reassuring to patients. Further risk reduction is expected from prophylactic gynecologic surgery. Continued investigations into genetic links with melanoma are warranted.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065288546

Download citation: RISBibTeXText

PMID: 29488126

DOI: 10.1007/s10549-018-4729-7


Related references

No impact of breast magnetic resonance imaging on 15-year outcomes in patients with ductal carcinoma in situ or early-stage invasive breast cancer managed with breast conservation therapy. Cancer 123(8): 1324-1332, 2016

Relationship of breast magnetic resonance imaging to outcome after breast-conservation treatment with radiation for women with early-stage invasive breast carcinoma or ductal carcinoma in situ. Journal of Clinical Oncology 26(3): 386-391, 2008

Long-term clinical and cosmetic outcomes after breast conservation treatment for women with early-stage breast carcinoma according to the type of breast boost. International Journal of Radiation Oncology, Biology, Physics 79(4): 1048-1054, 2011

A longitudinal study of factors associated with perceived risk of recurrence in women with ductal carcinoma in situ and early-stage invasive breast cancer. Breast Cancer Research and Treatment 124(3): 835-844, 2011

Long-term results for women with mammographically detected ductal carcinoma in-situ of the breast treated with breast-conserving surgery and definitive breast irradiation. International Journal of Radiation Oncology Biology Physics 57(2 Suppl.): S240-S241, 2003

Outcomes of low-risk ductal carcinoma in situ in Southeast Asian women treated with breast conservation therapy. International Journal of Radiation Oncology, Biology, Physics 88(5): 998-1003, 2014

Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer 103(6): 1137-1146, 2005

Relationship of family history and outcome after breast conservation therapy in women with ductal carcinoma in situ of the breast. International Journal of Radiation Oncology Biology Physics 48(4): 933-942, November 1, 2000

Relationship of family history and outcome after breast conservation therapy in women with ductal carcinoma in situ of the breast. International Journal of Radiation Oncology Biology Physics 45(3 Suppl. ): 230-231, 1999

Cardiac morbidity and mortality in women with ductal carcinoma in situ of the breast treated with breast conservation therapy. Breast Journal 17(5): 470-476, 2012

Breast conservation therapy for ductal carcinoma in situ (DCIS): does presentation of disease affect long-term outcomes?. International Journal of Clinical Oncology 19(3): 460-466, 2015

Lobular carcinoma in situ as a component of breast cancer: The long-term outcome in patients treated with breast-conservation therapy. International Journal of Radiation Oncology Biology Physics 40(2): 353-358, 1998

Long-term outcomes after breast conservation therapy for early stage breast cancer in a community setting. Breast Journal 12(2): 138-144, 2006

What is the significance of a lobular carcinoma in situ component in women treated with breast conserving therapy for early stage breast cancer?. International Journal of Radiation Oncology Biology Physics 27(Suppl. 1): 269, 1993

Long-Term Outcomes of Breast Conservation Therapy in Unifocal versus Multifocal Early Stage Breast Cancer Patients. International Journal of Radiation Oncology*biology*physics 99(2): E24-E25, 2017